Acceleron Pharma, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Acceleron Pharma, Inc. – Product Pipeline Review – 2016’, provides an overview of the Acceleron Pharma, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Acceleron Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Acceleron Pharma, Inc.

The report provides overview of Acceleron Pharma, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Acceleron Pharma, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Acceleron Pharma, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Acceleron Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acceleron Pharma, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acceleron Pharma, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Acceleron Pharma, Inc. Snapshot 6

Acceleron Pharma, Inc. Overview 6

Key Information 6

Key Facts 6

Acceleron Pharma, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Acceleron Pharma, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Acceleron Pharma, Inc. - Pipeline Products Glance 12

Acceleron Pharma, Inc. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Acceleron Pharma, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Acceleron Pharma, Inc. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Acceleron Pharma, Inc. - Drug Profiles 16

luspatercept 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

dalantercept 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

sotatercept 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ACE-083 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ACE-1332 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ACE-2395 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ACE-2494 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ACE-2536 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ACE-2798 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ACE-3891 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ACE-661 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Acceleron Pharma, Inc. - Pipeline Analysis 30

Acceleron Pharma, Inc. - Pipeline Products by Target 30

Acceleron Pharma, Inc. - Pipeline Products by Route of Administration 31

Acceleron Pharma, Inc. - Pipeline Products by Molecule Type 32

Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action 33

Acceleron Pharma, Inc. - Recent Pipeline Updates 34

Acceleron Pharma, Inc. - Dormant Projects 44

Acceleron Pharma, Inc. - Discontinued Pipeline Products 45

Discontinued Pipeline Product Profiles 45

ramatercept 45

Acceleron Pharma, Inc. - Locations And Subsidiaries 46

Head Office 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Acceleron Pharma, Inc., Key Information 6

Acceleron Pharma, Inc., Key Facts 6

Acceleron Pharma, Inc. – Pipeline by Indication, 2016 8

Acceleron Pharma, Inc. – Pipeline by Stage of Development, 2016 10

Acceleron Pharma, Inc. – Monotherapy Products in Pipeline, 2016 11

Acceleron Pharma, Inc. – Phase III, 2016 12

Acceleron Pharma, Inc. – Phase II, 2016 13

Acceleron Pharma, Inc. – Phase I, 2016 14

Acceleron Pharma, Inc. – Preclinical, 2016 15

Acceleron Pharma, Inc. – Pipeline by Target, 2016 30

Acceleron Pharma, Inc. – Pipeline by Route of Administration, 2016 31

Acceleron Pharma, Inc. – Pipeline by Molecule Type, 2016 32

Acceleron Pharma, Inc. – Pipeline Products by Mechanism of Action, 2016 33

Acceleron Pharma, Inc. – Recent Pipeline Updates, 2016 34

Acceleron Pharma, Inc. – Dormant Developmental Projects,2016 44

Acceleron Pharma, Inc. – Discontinued Pipeline Products, 2016 45

List of Figures

List of Figures

Acceleron Pharma, Inc. – Pipeline by Top 10 Indication, 2016 8

Acceleron Pharma, Inc. – Pipeline by Stage of Development, 2016 10

Acceleron Pharma, Inc. – Monotherapy Products in Pipeline, 2016 11

Acceleron Pharma, Inc. – Pipeline by Top 10 Target, 2016 30

Acceleron Pharma, Inc. – Pipeline by Top 10 Route of Administration, 2016 31

Acceleron Pharma, Inc. – Pipeline by Top 10 Molecule Type, 2016 32

Acceleron Pharma, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports